We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vitamin D Measured in Patients with Diabetic Foot

By LabMedica International staff writers
Posted on 19 Dec 2018
Print article
Image: The Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic for the quantitative determination of 25-hydroxyvitamin D (25(OH)D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency (Photo courtesy of Fujirebio).
Image: The Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic for the quantitative determination of 25-hydroxyvitamin D (25(OH)D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency (Photo courtesy of Fujirebio).
Peripheral artery disease (PAD) is the underlying predisposing factor in the etiology of the majority of diabetic feet. Vitamin D plays a role in calcium and bone metabolism and it is known to be an important immune modulator agent.

Osteoprotegerin (OPG) is a glycoprotein, which is a member of the tumor necrosis factor (TNF) family. Osteoprotegerin was first found in the bones and it acts as a strong anti-resorptive factor. The effect of osteoprotegerins is demonstrated by binding or neutralizing the receptor activator nuclear factor kappa B ligand (RANKL).

Medical scientists at the Bağcılar Training and Research Hospital (Istanbul, Turkey) conducted a prospective study on 105 patients including 58 patients with diabetic foot (42 males, 16 females; mean age 63.6 years; range, 31 to 90 years), who applied to the hospital between June 2014 and May 2015, and 47 newly diagnosed type 2 diabetes mellitus (DM) patients (27 males, 20 females; mean age 51.4 years; range, 29 to 85 years) (control group).

Serum concentration of 25-hydroxyvitamin D (25(OH)D) was determined by using electrochemiluminescence immunoassay utilized in fasting patients’ morning blood samples. Serum concentration of OPG was determined by enzyme-linked immunosorbent assay (ELISA) using the same blood samples. For OPG ELISA eBioscience kit, reference values for normal serum samples were 5-100 pg/mL.

The team found that osteoprotegerin levels in diabetic foot group were significantly higher than the control group. The 25(OH)D levels in diabetic foot group were significantly lower than the control group. There were positive correlations between OPG levels and C-reactive protein (CRP) and creatinine levels in patients with diabetic foot. The glycated hemoglobin (HbA1c) value did not differ significantly between the diabetic foot and control groups.

The authors concluded that elevated levels of OPG in patients with diabetic foot may display the severity of the clinical status due to its positive correlation with CRP and creatinine. They detected severe 25(OH)D deficiency in the majority of diabetic foot patients. Vitamin D supplementation may be required in diabetic foot patients to prevent unfavorable immunologic alterations. The study was published in the December 2018 in the journal Joint Diseases and Related Surgery.

Related Links:
Bağcılar Training and Research Hospital

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.